We are live on ! Find out more
EHI

Eagle Health Investments Portfolio holdings

AUM $603M
1-Year Est. Return 111.06%
This Fund
S&P 500
This Quarter Est. Return
-6.58%
1 Year Est. Return
+111.06%
3 Year Est. Return
+240.87%
5 Year Est. Return
+290.92%
10 Year Est. Return
–
AUM
$572M
AUM Growth
+$117M
Cap. Flow
+$164M
Cap. Flow %
28.7%
Top 10 Hldgs %
65.77%
Holding
37
New
7
Increased
17
Reduced
2
Closed
9

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$23.5M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$19.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$19.4M
4
ICLR icon
Icon
ICLR
+$15.2M
5
TEM
Tempus AI
TEM
+$14.6M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$23.1M
2
EXAS
Exact Sciences
EXAS
+$15M
3
NTRA icon
Natera
NTRA
+$13.2M
4
LEGN icon
Legend Biotech
LEGN
+$8.88M
5
SLNO
Soleno Therapeutics
SLNO
+$6.26M

Sector Composition

Rank Sector Weight
1 Healthcare 83.23%
2 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$93.2M 16.31%
+730,000
New +$91.1M
ARGX icon
2
argenx
ARGX
$54.1B
$55.7M 9.75%
76,336
+13,606
+22% +$10.6M
ICLR icon
3
Icon
ICLR
$12.9B
$39.7M 6.94%
358,500
+111,410
+45% +$15.2M
INSM icon
4
Insmed
INSM
$29.5B
$36.7M 6.41%
224,271
+13,371
+6% +$2.06M
GH icon
5
Guardant Health
GH
$22.7B
$28.7M 5.01%
310,281
+26,181
+9% +$2.63M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$13.3B
$28.6M 5%
505,809
+138,997
+38% +$8.1M
NTRA icon
7
Natera
NTRA
$46.3B
$24.4M 4.26%
121,877
-61,387
-33% -$13.2M
SRRK icon
8
Scholar Rock
SRRK
$6.21B
$24.3M 4.25%
494,019
+130,719
+36% +$5.86M
ILMN icon
9
Illumina
ILMN
$29B
$23.1M 4.04%
187,413
-43,748
-19% -$5.74M
TERN
10
DELISTED
Terns Pharmaceuticals
TERN
$21.7M 3.8%
412,497
+137,407
+50% +$5.64M
BBIO icon
11
BridgeBio Pharma
BBIO
$16.7B
$19.8M 3.47%
267,031
+7,731
+3% +$560K
ASND icon
12
Ascendis Pharma A/S
ASND
$16.5B
$19.8M 3.47%
+86,650
New +$19.4M
PTGX icon
13
Protagonist Therapeutics
PTGX
$9.64B
$18.9M 3.31%
179,322
+122,022
+213% +$10.8M
RARE icon
14
Ultragenyx Pharmaceutical
RARE
$2.65B
$18.5M 3.24%
+884,121
New +$19.9M
BSX icon
15
Boston Scientific
BSX
$73.5B
$18.4M 3.22%
+293,152
New +$23.5M
FTRE icon
16
Fortrea Holdings
FTRE
$1.81B
$12.3M 2.15%
1,307,560
+89,000
+7% +$1.14M
KYMR icon
17
Kymera Therapeutics
KYMR
$9B
$12.1M 2.12%
145,816
+9,516
+7% +$754K
PRCT icon
18
Procept Biorobotics
PRCT
$1.26B
$12.1M 2.12%
483,815
+175,381
+57% +$4.94M
RVMD icon
19
Revolution Medicines
RVMD
$43.8B
$11.6M 2.03%
119,464
+3,564
+3% +$360K
TEM
20
Tempus AI
TEM
$9.98B
$11.6M 2.03%
+256,269
New +$14.6M
CMPS
21
Compass Pathways
CMPS
$1.79B
$11.4M 1.99%
2,060,427
+541,039
+36% +$3.64M
CNTA
22
DELISTED
Centessa Pharmaceuticals
CNTA
$8.51M 1.49%
214,291
+111,191
+108% +$2.84M
ALKS icon
23
Alkermes
ALKS
$8.27B
$8.44M 1.48%
238,673
+156,873
+192% +$4.87M
ATAI icon
24
AtaiBeckley Inc
ATAI
$2.68B
$6.05M 1.06%
1,709,359
+30,959
+2% +$117K
PRCT icon
25
CALL
Procept Biorobotics
PRCT
$1.26B
$2.25M 0.39%
+90,000
New +$2.54M
1
2

Similar funds

PIFP
Partners in Financial Planning Salem, Virginia $603M AUM 12.72% 1-Year Est. Return
IECM
Intrinsic Edge Capital Management Chicago, Illinois $603M AUM 66.97% 1-Year Est. Return
ERWM
Elk River Wealth Management Denver, Colorado $602M AUM 22.77% 1-Year Est. Return
CIG
Capricorn Investment Group Palo Alto, California $602M AUM 165.22% 1-Year Est. Return
JHCP
Jackson Hole Capital Partners Tulsa, Oklahoma $605M AUM 22.77% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
NPCM
North Peak Capital Management New York $601M AUM 0.2% 1-Year Est. Return
OCAM
Onex Canada Asset Management Toronto, Ontario, Canada $601M AUM 15.16% 1-Year Est. Return

Eagle Health Investments's Q1 2026 Portfolio in Review

As of Q1 2026, Eagle Health Investments held 37 positions worth $572M, up 26% from $455M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Eagle Health Investments deployed $164M of net new capital in Q1 2026, opening 7 new positions and adding to 17 existing holdings. Its largest new stake was Boston Scientific: 293,152 shares worth $18.4M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Natera, an estimated $13.2M trimmed.

  • Eagle Health Investments's largest Q1 2026 buy was Boston Scientific: 293,152 shares worth $18.4M.
  • Eagle Health Investments added most to Icon in Q1 2026, an estimated $15.2M increase.
  • Eagle Health Investments's biggest Q1 2026 reduction was Natera, cutting an estimated $13.2M.
  • Eagle Health Investments fully exited Neurocrine Biosciences in Q1 2026, selling an estimated $23.1M.
  • Eagle Health Investments's ten largest holdings make up 66% of its $572M portfolio in Q1 2026.
  • Eagle Health Investments opened 7 new positions and closed 9 in Q1 2026.
  • Eagle Health Investments's portfolio value rose 26% quarter-over-quarter to $572M.

Based on Eagle Health Investments's 13F filing for Q1 2026, filed 15 May 2026.